{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:33:16Z","timestamp":1789871596075,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["R01CASS1918"],"award-info":[{"award-number":["R01CASS1918"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CASS1918"],"award-info":[{"award-number":["R01CASS1918"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ajog.2021.05.038","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T02:30:56Z","timestamp":1622514656000},"page":"511.e1-511.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result"],"prefix":"10.1016","volume":"225","author":[{"given":"Talia H.R.","family":"Strang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gottschlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-120X","authenticated-orcid":false,"given":"Darrel A.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovedeep","family":"Gondara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Niekerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina S.","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-8748","authenticated-orcid":false,"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.05.038_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ajog.2021.05.038_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ajog.2021.05.038_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002388","article-title":"Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial","volume":"14","author":"Canfell","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajog.2021.05.038_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.05.038_bib6","doi-asserted-by":"crossref","first-page":"e7789","DOI":"10.1136\/bmj.e7789","article-title":"Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland","volume":"345","author":"Leinonen","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2021.05.038_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajog.2021.05.038_bib8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer","volume":"357","author":"Mayrand","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.05.038_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/jnci\/djy192","article-title":"Role of screening history in clinical meaning and optimal management of positive cervical screening results","volume":"111","author":"Castle","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2021.05.038_bib10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/ijc.30385","article-title":"Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial","volume":"139","author":"Isidean","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2021.05.038_bib11","doi-asserted-by":"crossref","first-page":"dju153","DOI":"10.1093\/jnci\/dju153","article-title":"Reassurance Against future risk of precancer and cancer conferred by a negative human papillomavirus test","volume":"106","author":"Gage","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ajog.2021.05.038_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdp471","article-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening--summary document","volume":"21","author":"Arbyn","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2021.05.038_bib15","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1055-9965.EPI-08-0306","article-title":"Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia","volume":"17","author":"Cuschieri","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.05.038_bib17","first-page":"1917","article-title":"Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study","volume":"107","author":"Ogilvie","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.05.038_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2407-10-111","article-title":"A\u00a0randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial)","volume":"10","author":"Ogilvie","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2021.05.038_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.30454","article-title":"HPV for cervical cancer screening (HPV FOCAL): complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer","volume":"140","author":"Ogilvie","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2021.05.038_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1055-9965.EPI-20-1177","article-title":"Assessing 10-year safety of a single negative HPV test for cervical cancer screening: evidence from FOCAL-DECADE cohort","volume":"30","author":"Gottschlich","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2021.05.038_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1016\/j.ajog.2021.05.038_bib24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/JCM.03386-12","article-title":"Development and characterization of the cobas human papillomavirus test","volume":"51","author":"Rao","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ajog.2021.05.038_bib25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12885-015-1959-5","article-title":"Comparison of the Roche cobas\u00ae 4800 and Digene Hybrid Capture\u00ae 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial","volume":"15","author":"Cook","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2021.05.038_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcv.2014.11.017","article-title":"Comparison of the Roche Cobas\u00ae 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia","volume":"62","author":"Phillips","year":"2015","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ajog.2021.05.038_bib27","doi-asserted-by":"crossref","first-page":"e58153","DOI":"10.1371\/journal.pone.0058153","article-title":"HPV Testing by cobas HPV Test in a Population from Catalonia","volume":"8","author":"Lloveras","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2021.05.038_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/JCM.02147-10","article-title":"APTIMA HPV E6\/E7 mRNA test is as sensitive as hybrid capture 2 assay but more specific at detecting cervical precancer and cancer","volume":"49","author":"Ratnam","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ajog.2021.05.038_bib29","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JCM.01013-15","article-title":"Head-to-head comparison of the RNA-based APTIMA human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany","volume":"53","author":"Iftner","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ajog.2021.05.038_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.03558-14","article-title":"Comparison of human papillomavirus detection by APTIMA HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology","volume":"53","author":"Castle","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ajog.2021.05.038_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1701-2163(15)30255-3","article-title":"Projected impact of HPV and LBC primary testing on rates of referral for colposcopy in a Canadian Cervical Cancer Screening Program","volume":"37","author":"Coldman","year":"2015","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2021.05.038_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2016.12.004","article-title":"APTIMA HPV Assay versus Hybrid Capture\u00ae 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial","volume":"87","author":"Cook","year":"2017","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ajog.2021.05.038_bib33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dc.23930","article-title":"Human papillomavirus detection with genotyping by the cobas and APTIMA assays: significant differences in HPV 16 detection?","volume":"46","author":"Chorny","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ajog.2021.05.038_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2018.09.004","article-title":"Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial","volume":"108","author":"Cook","year":"2018","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ajog.2021.05.038_bib35","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821006062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821006062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:42Z","timestamp":1757590482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821006062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0002937821006062"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.038","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}